saroglitazar

Description: Saroglitazar (ZYH1; Lipaglyn) is an approved drug for the treatment of type 2 diabetes mellitus and dyslipidemia, acting as a novel dual PPAR alpha/gamma agonist. It is approved for use in India by the Drug Controller General of India. Saroglitazar has demonstrated reduction of triglycerides (TG), LDL cholesterol, VLDL cholesterol, non-HDL cholesterol and an increase in HDL cholesterol a characteristic hallmark of atherogenic diabetic dyslipidemia (ADD). Saroglitazar is novel first in class drug which acts as a dual PPAR agonist at the subtypes alpha (alpha) and gamma (gamma) of the peroxisome proliferator-activated receptor (PPAR). Agonist action at PPARalpha lowers high blood triglycerides, and agonist action on PPARgamma improves insulin resistance and consequently lowers blood sugar.

References: Saroglitazar, a novel PPARalpha/gamma agonist with predominant PPARalpha activity, showslipid-lowering and insulin-sensitizing effects in preclinical models.Pharmacol Res Perspect. 2015 Jun; 3(3):e00136.

Related CAS #: 1639792-20-3 (magnesium) 495399-09-2 (free)